Nuron Biotech develops vaccines and specialty biologics for the prevention and treatment of infectious and neurodegenerative diseases.
Nuron Biotech Inc. develops specialty biologics and vaccines. Its product pipeline comprises central nervous system products, such as NU100, a recombinant human interferon beta-1b for the treatment of relapsing remitting multiple sclerosis; wound healing products, including NU200, a recombinant human epidermal growth factor product for healing diabetic foot ulcers and burns; and HibTITER, a conjugate vaccine. The company was founded in 2010 and is based in Exton, Pennsylvania.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 12, 2014 | Private Equity(PE) | $22.70M | 1 | — | — | Detail |
Dec 26, 2012 | Private Equity(PE) | $80M | 1 | HealthCare Royalty Partners | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
HealthCare Royalty Partners | — | Private Equity(PE) |